Postmenopausal hormone therapy: Who now takes it and do they differ from non-users?

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 2, 2006, Pages 128-135

  Taylor, Anne W ^a   Maclennan, Alastair H ^a   Avery, Jodie C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Hormone therapy; Prevalence; Representative population surveys

Indexed keywords

HORMONE;

ADULT; AGE DISTRIBUTION; AGED; ALTERNATIVE MEDICINE; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG USE; EDUCATION; EMPLOYMENT; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; INCOME; MARRIAGE; MENOPAUSAL SYNDROME; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SOCIAL STATUS; TREATMENT DURATION;

AGE FACTORS; ANALYSIS OF VARIANCE; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; ODDS RATIO; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PREVALENCE; PROBABILITY; RISK ASSESSMENT; SOUTH AUSTRALIA;

EID: 33645360014     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00542.x     Document Type: Article

References (52)

1. MacLennan AH, Taylor AW, Wilson D. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995; 163: 420-422.
2. Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas 1996; 23: 47-53.
3. Carr BR. HRT management: The American experience. Eur J Obstet Gynaecol Reprod Biol 1996; 64: S17-S20.
4. Stamper MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63.
5. Grodstein F, Stampfer MJ, Manson JE et al. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N Eng J Med 1996; 335: 453-461.
6. O'Connell D, Robertson J, Henry D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of the treatment effects. Climacteric 1998; 1: 112-123.
7. Abrams J. Hormones and the cardiologist. Clin Cardiol 1998; 21: 218-222.
8. MacLennan A, Taylor A, Wilson D. Hormone therapy use after the Women's Health Initiative. Climacteric 2004; 7: 138-142.
9. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
10. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. Br Med J 2003; 327: 845-846.
11. Ettinger B, Grady D, Tosteson ANA, Pressman A, Macer JL. Effects of Women's Health Initiative on women's decision to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003; 102: 1225-1232.
12. Barber CA, Margolis K, Luepker RV, Arnett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy. J Women's Health 2004; 13: 975-985.
13. Bilgrami I, Blower K, Feng J, Stefanko G, Tan E. Changes in the use of hormone replacement therapy in New Zealand following the publication of the Women's Health Initiative trial. N Z Med J 2004; 117: U1175.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal; women: principal; results from the Women's Health Initiative randomised controlled trial. J Am Med Assoc 2002; 288: 321-333.
15. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestogen and the risk of coronary heart disease. N Eng Med 2003; 349: 532-534.
16. Aubuchon M, Santoro N. Lessons learnt from the WHI: HRT requires a cautious and individualised approach. Geriatrics 2004; 59: 22-26.
17. Bluming AZ. Hormone replacement therapy: The debate should continue. Geriatrics 2004; 59: 30-31, 35-37.
18. Genazzi AR, Gambacciani M. A personal initiative for women's health: To challenge the Women's Health Iitiative. Gynecol Endocrinol. 2002; 16: 255-257.
19. Harman SM, Brinton EA, Ceders M et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12.
20. MacLennan AH, Henderson VW, Paine BJ et al. Hormone therapy, timing of initiation, and cognition in women over 60 years -The REMEMBER pilot study. Menopause 2006; 13: 28-36.
21. Jacobs HS. Not for everybody. Br Med J. 1996; 313: 351-352.
22. Handa VL, Landerman R, Hanlon JT, Harris T, Cohen HJ. Do older women use estrogen replacement? Data from the Duke Established Populations for Epidemiological Studies of the elderly (EPESE). J Am Geriatr Soc 1996; 44: 1-6.
23. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991; 115.
24. Toozs-Hobson P, Cardozo L. Hormone replacement therapy for all? Universal prescription is desirable. Br Med J 1996; 313: 350-351.
25. Cauley J, Cummings SR, Blcak DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in older women. Am J Obstet Gynecol 1990; 5: 1438-1444.
26. Ekstrom H, Esseveld J, Hovelius B. Associations between attitudes towards hormone therapy and current use of it in middle-aged women. Maturitas 2003; 46: 45-57.
27. Hays J, Ockene JK, Brunner RL et al. Effects of estrongen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-1854.
28. Welton A, Hepworth J, Collins N et al. Decision making about hormone replacement therapy by women in England and Scotland. Climacteric 2004; 7: 41-49.
29. Wilson DH, Taylor AW, MacLennan AH. Health status of hormone replacement therapy users and non-users as determined by the SF-36 quality of life dimension. Climacteric 1998; 1: 50-54.
30. MacLennan AH, MacLennan A, Wilson D. The prevalence of oestrogen replacement therapy in South Australia. Maturitas 1993; 16: 175-183.
31. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy - Prevalence, compliance and the 'healthy women' notion. Climacteric 1998; 1: 42-49.
32. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy in women at risk of cardiovascular disease in South Australia in 1997. Med J Aust 1999; 170: 524-527.
33. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy use over a decade in an Australian population. Climacteric 2002; 5: 351-356.
34. Ware JE, Kosinski M, Dewey J. How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI: Quality Metric Incorporated, 2000.
35. Hawthorne G, Richardson J, Day N. Using the Assessment of Quality of Life (AQoL), Version 1. West Heidelberg, Victoria: Centre for Health Program Evaluation, 2000.
36. Wilson D, Wakefield M, Taylor A. The South Australian Health Omnibus Survey. Health Promotion J Aust. 1992; 2: 47-49.
37. Avery J, Gill T, MacLennan AH, Chittleborough C, Grant J, Taylor A. The impact of incontinence on health-related quality of life in a South Australian population sample. Aust N Z J Public Health 2004; 28: 173-179.
38. MacLennan A, Taylor A, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. Br J Obstet Gynaecol December 2000; 107: 1460-1470.
39. Taylor A, Dal Grande E, Wilson D. The South Australian Health Omnibus Survey 15 years on: Has public health benefited ? Public Health Bulletin South Australia 2006; 3: 30-32.
40. Australian Bureau of Statistics. Population by Age and Sex. South Australia, June 2000. 2001. ABS catalogue number 3235.4. Canberra: Commonwealth of Australia.
41. Australian Bureau of Statistics. Census of Population and Housing. Socio-Economic Indexes for Areas. Information paper. ABS Catalogue no. 2039.0. 1996.
42. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of A WHO Consultation on Obesity. Geneva, 3-5, 1997. Geneva: WHO, 2000.
43. SPSS. SPSS Advanced Statistics 13. 0. Chicago, IL, USA: SPSS Inc, 2004.
44. Dean AD, Dean JA, Coulombier D et al. Epi Info, Version 6: A Word-Processing, Database and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention, 1995.
45. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley, 1989.
46. Brennan RM, Crespo CJ, Wactawski-Wende J. Health behaviours and other characteristics of women on hormone therapy: Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Menopause 2004; 11: 536-542.
47. Welton A, Hepworth J, Colins N et al. Women's International Study of long duration Oestrogen after menopause (WISDOM) team. Decisions-making about hormone replacement therapy by women in England and Scotland. Climacteric 2004; 7: 41-49.
48. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy; a placebo-controlled study. Menopause 2003; 10: 29-36.
49. Col NF, Weber G, Stiggelbout A, Chou J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: An updated decision model. Arch Intern Med 2004; 164: 1634-1640.
50. Salpeter S. Hormone therapy for younger postmenopausal women: How can we make sense out of the evidence? Climacteric 2005; 8: 307-310.
51. Stevenson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005; 51: 113-126.
52. Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone therapy? Int J Cardiol 2003; 87: 1-8.